BACKGROUND: Studies of the effect of right ventricular ejection fraction (RVEF) on outcomes in heart failure (HF) are limited by small sample size and short follow-up. METHODS AND RESULTS: We examined the effect of baseline RVEF on outcomes in 2008 Beta-Blocker Evaluation of Survival Trial (BEST) participants with HF and left ventricular ejection fraction <or=35% during 24 months of mean follow-up. RVEF, estimated by gated-equilibrium radionuclide ventriculography, was used to categorize patients into 4 RVEF groups: >or=40% (n=733), 30% to 39% (n=531), 20% to 29% (n=473), and <20% (n=271). Unadjusted rates for all-cause mortality in patients with RVEF >or=40%, 30% to 39%, 20% to 29%, and <20% were 27%, 32%, 35%, and 47%, respectively. When compared with patients with RVEF >or=40%, unadjusted hazard ratios and 95% confidence intervals for all-cause mortality for those with RVEF 30% to 39%, 20% to 29%, and <20% were 1.19 (0.97 to 1.46; P=0.087), 1.45 (1.17 to 1.78; P=0.001), and 1.98 (1.59 to 2.47; P<0.0001), respectively. Respective multivariable-adjusted hazard ratios (95% confidence intervals) for all-cause mortality associated with RVEF 30% to 39%, 20% to 29%, and <20% were 1.07 (0.87 to 1.32; P=0.518), 1.12 (0.89 to 1.40; P=0.328), and 1.32 (1.02 to 1.71; P=0.034), respectively. Adjusted hazard ratios (95% confidence intervals) for other outcomes associated with RVEF <20% (compared with >or=40%) were as follows: cardiovascular mortality, 1.33 (1.01 to 1.76; P=0.041); HF mortality, 1.61 (1.03 to 2.52; P=0.037); sudden cardiac death, 1.29 (0.87 to 1.91; P=0.212); all-cause hospitalization, 1.21 (1.00 to 1.47; P=0.056); and HF hospitalization, 1.39 (1.10 to 1.77; P=0.007). CONCLUSIONS: Baseline RVEF <20% is a significant independent predictor of mortality and HF hospitalization in systolic HF.
BACKGROUND: Studies of the effect of right ventricular ejection fraction (RVEF) on outcomes in heart failure (HF) are limited by small sample size and short follow-up. METHODS AND RESULTS: We examined the effect of baseline RVEF on outcomes in 2008 Beta-Blocker Evaluation of Survival Trial (BEST) participants with HF and left ventricular ejection fraction <or=35% during 24 months of mean follow-up. RVEF, estimated by gated-equilibrium radionuclide ventriculography, was used to categorize patients into 4 RVEF groups: >or=40% (n=733), 30% to 39% (n=531), 20% to 29% (n=473), and <20% (n=271). Unadjusted rates for all-cause mortality in patients with RVEF >or=40%, 30% to 39%, 20% to 29%, and <20% were 27%, 32%, 35%, and 47%, respectively. When compared with patients with RVEF >or=40%, unadjusted hazard ratios and 95% confidence intervals for all-cause mortality for those with RVEF 30% to 39%, 20% to 29%, and <20% were 1.19 (0.97 to 1.46; P=0.087), 1.45 (1.17 to 1.78; P=0.001), and 1.98 (1.59 to 2.47; P<0.0001), respectively. Respective multivariable-adjusted hazard ratios (95% confidence intervals) for all-cause mortality associated with RVEF 30% to 39%, 20% to 29%, and <20% were 1.07 (0.87 to 1.32; P=0.518), 1.12 (0.89 to 1.40; P=0.328), and 1.32 (1.02 to 1.71; P=0.034), respectively. Adjusted hazard ratios (95% confidence intervals) for other outcomes associated with RVEF <20% (compared with >or=40%) were as follows: cardiovascular mortality, 1.33 (1.01 to 1.76; P=0.041); HF mortality, 1.61 (1.03 to 2.52; P=0.037); sudden cardiac death, 1.29 (0.87 to 1.91; P=0.212); all-cause hospitalization, 1.21 (1.00 to 1.47; P=0.056); and HF hospitalization, 1.39 (1.10 to 1.77; P=0.007). CONCLUSIONS: Baseline RVEF <20% is a significant independent predictor of mortality and HF hospitalization in systolic HF.
Authors: A Gavazzi; C Berzuini; C Campana; C Inserra; M Ponzetta; R Sebastiani; S Ghio; F Recusani Journal: J Heart Lung Transplant Date: 1997-07 Impact factor: 10.247
Authors: Norbert F Voelkel; Robert A Quaife; Leslie A Leinwand; Robyn J Barst; Michael D McGoon; Daniel R Meldrum; Jocelyn Dupuis; Carlin S Long; Lewis J Rubin; Frank W Smart; Yuichiro J Suzuki; Mark Gladwin; Elizabeth M Denholm; Dorothy B Gail Journal: Circulation Date: 2006-10-24 Impact factor: 29.690
Authors: M R Bristow; L S Zisman; B D Lowes; W T Abraham; D B Badesch; B M Groves; N F Voelkel; D M Lynch; R A Quaife Journal: Chest Date: 1998-07 Impact factor: 9.410
Authors: Ali Ahmed; Gilbert J Perry; Jerome L Fleg; Thomas E Love; David C Goff; Dalane W Kitzman Journal: Am Heart J Date: 2006-11 Impact factor: 4.749
Authors: P de Groote; A Millaire; C Foucher-Hossein; O Nugue; X Marchandise; G Ducloux; J M Lablanche Journal: J Am Coll Cardiol Date: 1998-10 Impact factor: 24.094
Authors: Selma F Mohammed; Imad Hussain; Omar F AbouEzzeddine; Omar F Abou Ezzeddine; Hiroyuki Takahama; Susan H Kwon; Paul Forfia; Véronique L Roger; Margaret M Redfield Journal: Circulation Date: 2014-11-12 Impact factor: 29.690
Authors: Neal A Chatterjee; Ravi V Shah; Venkatesh L Murthy; Amy Praestgaard; Sanjiv J Shah; Corey E Ventetuolo; R Graham Barr; Richard Kronmal; Joao A C Lima; David A Bluemke; Michael Jerosch-Herold; Alvaro Alonso; Steven M Kawut Journal: Circ Arrhythm Electrophysiol Date: 2017-01
Authors: Markus A Horvath; Isaac Wamala; Eric Rytkin; Elizabeth Doyle; Christopher J Payne; Thomas Thalhofer; Ignacio Berra; Anna Solovyeva; Mossab Saeed; Sara Hendren; Ellen T Roche; Pedro J Del Nido; Conor J Walsh; Nikolay V Vasilyev Journal: Ann Biomed Eng Date: 2017-05-16 Impact factor: 3.934
Authors: Kotaro Nochioka; Gabriela Querejeta Roca; Brian Claggett; Tor Biering-Sørensen; Kunihiro Matsushita; Chung-Lieh Hung; Scott D Solomon; Dalane Kitzman; Amil M Shah Journal: JAMA Cardiol Date: 2018-10-01 Impact factor: 14.676